Welcome to Cardiology Today – Recorded November 14, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic cardiomyopathy and ventricular tachycardia. Key takeaway: Sacubitril-Valsartan for Chemo Cardiotoxicity. Article Links: Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock. (The New England journal of medicine) Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. (Circulation) Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. (European heart journal) Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. (European heart journal) Article 5: Exploring postmortem practices for cardiac device interrogation in the UK. (Heart (British Cardiac Society)) Full episode page: https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/ Featured Articles Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159885 Summary: This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study’s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population. Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41230611 Summary: The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment. Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879135 Summary: The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator u